(redirected from medroxyprogesterone acetate)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for medroxyprogesterone

a progestin compound (trade name Provera) used to treat menstrual disorders


References in periodicals archive ?
I couldn't agree more that the black box warning for depot medroxyprogesterone acetate (DMPA) should be removed by the FDA.
By itself, this finding should not prompt a change in the use of injectable medroxyprogesterone acetate (Depo-Provera) in adolescent girls, he told this newspaper.
11), the dosage of medroxyprogesterone acetate used in Dr.
Drug Dosage conjugated equine estrogen and 0.625 mg estrogen and medroxyprogesterone acetate 2.5 mg medroxyproges- (Prempro) terone/day estradiol and norethindrone 1 mg estradioland acetate (Activella) 0.5 mg norethindrone/day ethinyl estradiol and norethindrone 5 [micro]g ethinyl acetate (femhrt) estradiol and 1 mg norethindrone/day estradiol and norethindrone 0.05 mg estradiol and acetate (CombiPatch) 0.14 mg norethindrone/ day estradiol and norgestimate (Ortho- 1 mg estradiol/day and Prefest) 0.09 mg norgestimate/day for 3 days.
Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density.
Last month the FDA approved a Prempro formulation (0.3 mg of conjugated estrogens and 1.5 mg of medroxyprogesterone acetate) for the treatment of moderate to severe menopausal symptoms and the prevention of postmenopausal osteoporosis.
Chronic use of depot medroxyprogesterone acetate may have an adverse effect on cardiovascular health, a small, nonrandomized study suggests.
Progestin-only contraception--a diverse group of oral (progestin-only pills, or so-called minipills), injectable (depot medroxyprogesterone acetate), intrauterine (the levonorgestrel intrauterine system), and implantable (etonogestrel implant) methods--may offer advantages over estrogen-containing contraception:
Depot medroxyprogesterone acetate (Depo-Provera) and levonorgestrel (Norplant) use in adolescents among clinicians in Northern Europe and the United States.
In the first trial, 2,763 women with CHD, mean age 67, were randomized to receive 0.625 mg/day of conjugated estrogens and 2.5 mg/day of medroxyprogesterone acetate, or placebo.
I would add that oral micronized progesterone does not diminish vaginal blood flow as medroxyprogesterone acetate has been shown to do.
* Note that oral contraceptives and medroxyprogesterone acetate (DepoProvera) may thin the vaginal epithelium and promote viral shedding.
About 53% of women on Lunelle (medroxyprogesterone acetate and estradiol cypionate) are fertile again within 6 months of their last injection regardless of their length of use.